Skip to content

    Biocon Limited

    Global biopharma group making biosimilars, insulins, generics and CRDMO services via Syngene.

    Healthcare
    Healthcare
    View BIOCON earnings calls
    ₹415.5
    +5.82% from avg

    Overview

    Price

    ₹415.5

    Market Cap

    ₹71.1k Cr

    Sector

    Healthcare

    Healthcare

    Rank

    2

    Performance

    Explore BIOCON

    Promise TrackerConcall Analysis

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly

    Balance Sheet

    Balance Sheet

    ₹ Cr · Annual
    Line itemFY20FY21FY22FY23FY24FY25FY26FY26
    LiabilitiesEquity Capital600600600600600600668810
    Reserves6.1k7.0k7.8k17.3k19.2k21.0k26.1k33.2k
    Borrowings2.7k4.5k5.1k18.0k16.3k18.4k16.5k15.4k
    Other Liabilities5.0k6.4k6.8k15.9k19.7k18.5k19.4k13.9k
    Total Liabilities14.4k18.5k20.3k51.7k55.8k58.5k62.8k63.4k
    AssetsFixed Assets6.0k6.4k6.6k29.5k30.6k32.0k37.3k36.5k
    CWIP2.2k2.8k4.1k7.3k8.0k8.5k4.7k7.0k
    Investments9662.0k1.6k2.1k1.0k1.1k2.3k1.8k
    Other Assets5.3k7.4k8.1k12.9k16.1k16.9k18.5k18.2k
    Total Assets14.4k18.5k20.3k51.7k55.8k58.5k62.8k63.4k

    Valuation

    Too capital-hungry for an earnings DCF

    For capital-heavy businesses (telecom, power, heavy manufacturing) reported profit ignores the cash needed just to stand still. We'd systematically overvalue it, so we don't show a number.

    BIOCON · CAPITAL_INTENSIVE

    Learn to analyse Biocon Limited

    Guides on how to read this kind of business and the numbers that matter.